Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2003
06/26/2003US20030118642 Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
06/26/2003US20030118641 Abuse-resistant sustained-release opioid formulation
06/26/2003US20030118640 Pharmaceutical formulations comprising sodium amoxycillin and potassium clavulanate
06/26/2003US20030118638 Oral pharmaceutical products containing 17 beta-estradiol-3-lower alkanoate, method of administering the same and process of preparation
06/26/2003US20030118637 Preventing antibody-induced anemia by administering a complexes of bisphosphonate
06/26/2003US20030118634 Administering a bisphosphonate; risedronate, ibandronate, pamidronate, alendronate, cimadronate, tiludronate; osteoporosis
06/26/2003US20030118633 Treating unstable or overactive urinary bladder by administering an antimuscarinic agent and an estrogen agonist
06/26/2003US20030118632 Methods and compositions for treating carpal tunnel syndrome
06/26/2003US20030118631 Soluble cellulose molecules with carboxyl groups and a pharmaceutically effective agent with amino groups attached to the carboxyl group of the cellulose
06/26/2003US20030118623 Composition based on etyl ester of linoleic acid and triethyl ester of citric acid for topical use in the treatment of seborrhea and acne
06/26/2003US20030118617 Resveratrol analogues
06/26/2003US20030118616 Cosmetic material containing triple- encapsulated retinol
06/26/2003US20030118613 Compositions having improved delivery of actives
06/26/2003US20030118611 Epitopes confirmed to be recognized by T-cells derived from herpetic lesions or uterine cervix; vaccination
06/26/2003US20030118606 Contains mycelium fraction of a product obtained by incubation of mycelia of Ganoderma boninense and induces production of interleukin 12; use as terminal cancer treatment or supplementary food preparation
06/26/2003US20030118594 Stable formulations of mhc-peptide complexes
06/26/2003US20030118576 Administering to a human or an animal a therapeutically amount of coenzyme Q10 or a derivative, effective to treat or prevent apoptotic events occurring in ocular degenerative pathologies of posterior part of the eye
06/26/2003US20030118575 Administering a pyrazole compound containing urea or thiourea groups, twice daily to a patient in need of treatment of a cytokine mediated disease
06/26/2003US20030118564 Intra-tumoral administration of il-12 encoding nucleic acid molecules
06/26/2003US20030118546 Genetic engineering; polypeptides; antitumor agent
06/26/2003US20030118545 Methods and compositions for treating mammalian nerve tissue injuries
06/26/2003US20030118541 Controlling drug resistance; intensify therapy; increas accumulation in cell
06/26/2003US20030118540 Composition
06/26/2003US20030118539 Polyamines and analogs for protecting cells during cancer chemotherapy and radiotherapy
06/26/2003US20030118536 Topical compositions and methods for treatment of adverse effects of ionizing radiation
06/26/2003US20030118533 Topical compositions containing fluid-absorbent solids and adhesive fluids
06/26/2003US20030118528 Topical delivery of codrugs
06/26/2003US20030118526 Mixture containing sunscreen agent; storage stability
06/26/2003US20030118517 Topical oral dosage forms containing bismuth compounds
06/26/2003US20030118514 Compositions for inhalation
06/26/2003US20030118513 Lung administering; bioavailability
06/26/2003US20030118512 Volatilization of a drug from an inclusion complex
06/26/2003US20030118511 Skin disorders; psoriasis
06/26/2003US20030118507 Methods of using 46828, a human acyl-CoA synthetase
06/26/2003US20030117579 Medical devices having antimicrobial coatings thereon
06/26/2003CA2822457A1 Methods and compositions for controlled resease of drugs
06/26/2003CA2746308A1 Method for treating human papilloma virus
06/26/2003CA2510128A1 Composition, synthesis and therapeutic applications of polyamines
06/26/2003CA2507846A1 Chitosan oligosaccharides and uses thereof
06/26/2003CA2497195A1 Methods and compositions for controlled release of drugs
06/26/2003CA2473938A1 Human adam-10 inhibitors
06/26/2003CA2473877A1 Substituted beta-aminoalcohols as pharmaceutical preparations
06/26/2003CA2471777A1 Novel death associated proteins of the thap family and related par4 pathways involved in apoptosis control
06/26/2003CA2471589A1 Pharmaceutical conjugates with enhanced pharmacokinetic characteristics
06/26/2003CA2471500A1 Substituted 1,5-diaminopentan-3-ol compounds
06/26/2003CA2471260A1 Compositions and methods for high sorption of skin materials and delivery of sulfur
06/26/2003CA2471237A1 Adhesion inhibition of moulds
06/26/2003CA2471235A1 Inhibition of the asexual reproduction of fungi
06/26/2003CA2470811A1 Protease inhibitors of the coagulation cascade isolated from dysidea sponges
06/26/2003CA2470763A1 Novel pharmaceutical composition of interferon gamma or pirfenidone with molecular diagnostics for the improved treatment of interstitial lung diseases
06/26/2003CA2470723A1 3,4-dihydro-1h-isoquinolin-2-yl-derivatives
06/26/2003CA2470640A1 Use of hmgb proteins and nucleic acids that code therefor
06/26/2003CA2470629A1 Stabilized brivudine topical formulations
06/26/2003CA2470624A1 Selective dopamine d3 receptor agonists for the treatment of sexual dysfunction
06/26/2003CA2470616A1 Hydroxyphenyl-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
06/26/2003CA2470590A1 Pharmaceutical composition comprising an oil/water/oil double microemulsion incorporated into a solid support
06/26/2003CA2470582A1 Mitocidal compositions and methods
06/26/2003CA2470567A1 Methods and compositions for treatment of central nervous system disorders
06/26/2003CA2470491A1 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar)
06/26/2003CA2470479A1 Polymorphs of clopidogrel hydrogensulfate
06/26/2003CA2470472A1 Aqueous ifosfamide composition
06/26/2003CA2470322A1 Methods for particle-assisted polynucleotide immunization using a pulsed electric field
06/26/2003CA2470311A1 Method of screening compounds
06/26/2003CA2470307A1 Protein kinase inhibitors
06/26/2003CA2470236A1 Lactams as tachykinin antagonists
06/26/2003CA2470214A1 3-(phenyl-alkoxy)-5-(phenyl)-pyridine derivatives and related compounds as kinase inhibitors for the treatment of cancer
06/26/2003CA2470210A1 Use of selective pde5 inhibitors for treating partial and global respiratory failure
06/26/2003CA2470209A1 Pre-formulation for the tabletting of natural mixtures of conjugated estrogens
06/26/2003CA2470204A1 Use of dsrnas in strategic therapeutic intervention of highly active antiretroviral therapy
06/26/2003CA2470060A1 Improvements in pharmaceutical compositions
06/26/2003CA2470009A1 The total synthesis of merrilactone a
06/26/2003CA2469976A1 Improvements in pharmaceutical compositions
06/26/2003CA2469950A1 Methods for treatment or prophylaxis of aldosterone-mediated pathogenic effectgs in a subject using an epoxy-steroidal aldosterone antagonist
06/26/2003CA2469944A1 Medicaments comprising n, n'-disubstituted piperazine compounds and their use
06/26/2003CA2469940A1 Solid compositions comprising compounds unstable to oxygen and method for stabilizing them
06/26/2003CA2469879A1 A novel sordarin derivative isolated from culture fermentations and functions as an antifungal agent
06/26/2003CA2469799A1 Use of a lysolipid for the preparation of a composition for transfection of a polynucleotide into a cell
06/26/2003CA2469790A1 Method for treating circadian rhythm disruptions
06/26/2003CA2469786A1 5, 6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists
06/26/2003CA2469663A1 Aminoalkyl-benzofuran-5-ol compounds for the treatment of glaucoma
06/26/2003CA2469305A1 Methods for preparing sodium-hydrogen exchanger type-1 inhibitors
06/26/2003CA2469302A1 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar)
06/26/2003CA2469205A1 Bioadhesive drug delivery system with enhanced gastric retention
06/26/2003CA2469200A1 Analgesic delivery systems and methods of use
06/26/2003CA2469108A1 A novel polymorph of sertraline hydrochloride and composition containing thereof, novel methods for preparation of sertraline hydrochloride polymorphs and amorphous form
06/26/2003CA2469048A1 Quinolinones as prostaglandin receptor ligands
06/26/2003CA2468978A1 Therapeutic heterocycles
06/26/2003CA2468880A1 Tetrahydrocarbazole derivatives as ligands for g-protein coupled receptors (gpcr)
06/26/2003CA2468783A1 Cis-imidazolines as mdm2 inhibitors
06/26/2003CA2468688A1 New process
06/26/2003CA2468687A1 Liquid bisphosphonate formulations for bone disorders
06/26/2003CA2468413A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase
06/26/2003CA2467780A1 N-carbacycle monosubstituted indolocarbazoles as protein kinase inhibitors
06/26/2003CA2467279A1 Solubilized topoisomerase poison agents
06/26/2003CA2466010A1 Method of obtaining 2-(2-nitrovinyl)-furan and the use thereof as a coccidiostatic
06/26/2003CA2465888A1 Topical compositions and methods for treatment of adverse effects of ionizing radiation
06/26/2003CA2453417A1 Nanoparticle delivery vehicle
06/25/2003EP1321526A2 Adenovirus-mediated gene transfer to cardiac and vascular smooth muscle
06/25/2003EP1321516A2 Hydrogel matrix for cellular tissue storage
06/25/2003EP1321476A2 Binding protein
1 ... 5426 5427 5428 5429 5430 5431 5432 5433 5434 5435 5436 5437 5438 5439 5440 5441 5442 5443 5444 5445 5446 ... 7860